神经内科用药禁忌总结

2015-12-29 医考课堂整理 医考课堂整理

1、高血压脑病或RPLS患者慎用ACEI类降压药,因其高血压有可能为肾动脉狭窄所致。2、有冠心病及其他严重的心血管疾病患者,有脑血管意外,动脉阻塞性疾病患者,禁用溴隐亭片;严重心律失常、心力衰竭、青光眼、消化性溃疡和有惊厥史者禁用左旋多巴片;对于有房室传导阻滞者 ,有骨髓抑制史者,禁用得理多。3、降压药的几种不良反应:(1)β受体阻滞剂、钙通道阻滞剂单用或联合应用时可能导致心脏抑制;(2)AC

1、高血压脑病或RPLS患者慎用ACEI类降压药,因其高血压有可能为肾动脉狭窄所致。

2、有冠心病及其他严重的心血管疾病患者,有脑血管意外,动脉阻塞性疾病患者,禁用溴隐亭片;严重心律失常、心力衰竭、青光眼、消化性溃疡和有惊厥史者禁用左旋多巴片;对于有房室传导阻滞者 ,有骨髓抑制史者,禁用得理多。

3、降压药的几种不良反应:

(1)β受体阻滞剂、钙通道阻滞剂单用或联合应用时可能导致心脏抑制;

(2)ACEI常见的不良反应为低血压,而且不能与保钾利尿剂长期合用;

(3)硝苯地平缓释片可能会引起患者出现双下肢水肿;

(4)利尿剂、β受体阻滞剂对血脂、血钠、血糖、血尿酸的代谢会有影响。

(5)心衰病人应用地高辛时合用立普妥会增加中毒风险;

(6)利血平用于急诊脑血管患者的高血压;

(7)西比灵与钙拮抗类降压药物临床上不应同时使用。

4、在临床工作中经常会遇到呃逆患者,这时候很多的医生可能会想到给予氟哌啶醇治疗。 然而较大剂量的氟哌啶醇在患有心脏病的患者中,可能会导致恶性神经阻滞综合症的可能。所以应用此药,须在充分了解患者心脏前提下使用。

5、脑血管病急性期,会出现不同程度血压升高,要视血压而定,急诊科常用舌下含化心痛定,肌注利血平,不适合。血压下降过快会加重缺血,如分水岭脑梗死的形成;对分水岭梗死患者使用降压药物时应该注意,应监控血压,防止血压下降后加重病情。

6、脑血管病慎用硝普钠和硝酸甘油,原因是:

(1)血压降低后引起大脑灌注不足;

(2)颅内血管扩张加重颅高压。使用硝普纳应严格控制剂量,密切观察血压变化。药液配置后存放时间不能超过四小时。

7、关于脑血管病急性期应用硝酸甘油的问题:

(1)请仔细阅读硝酸甘油的说明书,颅内压增高者为禁忌症!

(2)理论上,硝酸甘油扩张心脑血管,脑出血急性期的确应该避免!脑血管意外病人补液少用糖水:脑血管意外患者大脑处于缺氧状态,糖水补进去后,脑细胞在缺氧状态下会增加糖酵解,使乳酸堆积,加重脑损伤;脑血管意外病人合并心衰的不能用甘露醇脱水,输快了加重心衰,输慢了不管用。

8、活动性颅内出血者及严重颅内损伤急性期不可用胞磷胆碱;扩血管药物慎用于脑梗死急性期:大面积脑梗死早期以及高尿酸血症的缺血性脑血管患者慎用阿斯匹林,曾经有一个病人用阿司匹林后出现哮喘,耳鼻喉科会诊病人有鼻息肉。阿司匹林不宜与某些药同用,

(1)与维生素B1同服,会增加胃肠道反应;

(2)与抗凝药双香豆素合用,易致出血;

(3)与降糖药D860同用,易致低血糖反应;

(4)与肾上腺皮质激素合用,易诱发溃疡;

(5)与甲氨蝶呤同用,可增强其毒性;

(6)与速尿同用,容易造成水杨酸中毒;

(6)阿司匹林与地尔硫卓合用可使出血时间延长,手术前后不宜合用。

9、脑室外引流后一般不用甘露醇,甘露醇在颅内活动性出血者禁用(如脑出血急性期,特别是在6小时内,应用甘露醇可因扩容加重出血),SAH病人脱水太厉害,容易引起动脉瘤再破裂,硬膜下或外出血/积液,慎应脱水药物但颅内手术时除外。甘露醇应用的禁忌:尿闭,心功能不全,颅内活动性出血及血尿患者。

10、需要强调的药物是神经科常用药物-地塞米松,长期用副作用很多,大家都知道,但还是经常见到滥用,尤其是老年中风患者;平衡液中不加地塞米松,胰岛素不和维生素C合用。重症肌无力病人慎用激素;如果用,用药初期应该住院,并且严密观察,因为激素可以加重重症肌无力的病情。机制还不大清楚,可能的有:直接抑制N-M接头处的传递;通过增强胆碱酯酶抑制剂的作用,促发胆碱能危象;使血AchR抗体增多;早期加重和后来的疗效没关。地塞米松含氟,风湿病患者应慎用。

11、MG患者:奎宁、奎尼丁、普鲁卡因酰胺、青霉胺、心得安、苯妥英、锂、四环素及氨基糖甙类抗生素可使症状加剧,应避免使用。甲氯芬脂对兴奋过度,有锥体外系症状者忌用。ICH急性期禁用胞二磷胆碱。

12、奥力保克、西比灵不宜用于PD病人,加重锥体外系症状。  PD药物的大概禁忌:

(1)、安坦,禁用于青光眼患者;与金刚烷胺、抗胆碱药合用时,可加强抗胆碱作用,并可引起麻痹性肠梗阻;

(2)、金刚烷胺,禁用于孕妇和哺乳期妇女;癫痫、有精神病史者慎用;

(3)、左旋多巴,青光眼、糖尿病、心律失常、恶性黑色素瘤患者禁用;哺乳期妇女禁用。

(4)、司来吉兰与度冷丁合用时,可造成致命性的反应;

(5)、泰舒达,循环衰竭者及急性心梗者禁用。美多巴及泰舒达禁用于有精神症状的患者,其有诱发精神症状的副作用。

PD的药物治疗的禁忌症,粗略的总结如下:

(1),抗胆碱能药:安坦,开马君青光眼及前列腺患者禁用,老年患者可影响记忆功能,应慎用;

(2),金钢烷胺:有癫痫史,精神错乱,幻觉,充血性心力衰竭,肾功能不全,外周血管性水肿或直立性低血压的患者慎用金钢烷胺抗震颤麻痹;新生儿和1岁以下婴儿或哺乳期妇女禁用;

(3),L-Dopa类药物:美多芭,帕金宁在狭角型青光眼,精神病患者禁用,活动性消化道溃疡患者应慎用;

(4),DA受体激动剂:1)培高利特2)溴隐亭:副作用与左旋多巴类似,但错觉和幻觉常见,有精神病史者禁用,近期心肌梗死,严重周围血管病和消化性溃疡等是相对禁忌症 3)新型DA受体激动剂:派拉米苏,罗吡尼洛;

(5),MAO-B抑制剂:思吉宁,主要有口干,胃纳减退和体位性低血压等,胃溃疡患者慎用;

(6),COMT抑制剂:答是美,柯丹;7,中药或针灸对PD有一定的辅助作用。

13、补B1时忌用糖水,补钾时忌用糖水加胰岛素。VitB1的主要作用是以辅酶的方式参加糖代谢;缺乏时,使丙酮酸难于进入三羧酸循环氧化,造成丙酮酸及乳酸堆积,如此时再用糖会加重Vit B1的缺乏,造成酸性物质大量堆积,可诱发Wernicke 脑病发作,临床上甚至可出现急性昏迷。另外,大量葡萄糖输入时,亦需适当补充Vit B1。目的是补充钾的话,如用糖加胰岛素,会加重缺钾,至少是无效补钾;因为糖代谢需消耗钾。如目的不是补钾,则用糖用盐均可。

14、疑有VitB1缺乏者(Wernicke 脑病,脚气病,长期嗜酒,营养不良等),也应慎用肾上腺皮质激素;因其有对抗Vit B1的作用,阻碍丙酮酸的氧化,可诱发Wernicke 脑病发作,亦可使患者陷入昏迷,甚至呼吸停止。

15、脑活素不可以与平衡氨基酸注射液同一瓶中静滴。胰岛素配VitC在配伍表中禁忌,有糖尿病的患者慎用小牛血去蛋白提取物、血通(丹参川芎嗪)针(说明书描述)。

16、神经科中风合并糖尿病患者糖尿病酮症、糖尿病肾病需要禁用二甲双胍

17、706代血浆应慎用于糖尿病患者,临床上还遇到有患者使用后出现腮腺肿大。

18、(1)肿瘤的病人慎用维生素B12和叶酸,会促进肿瘤生长;

(2)隐球菌脑膜炎的病人慎用维生素B12,会促进隐球菌生长;

(3)结核性脑膜炎应用异烟肼的病人需用维生素B6,但要少于常规用量,会减弱异烟肼的效果;

(4)帕金森应用左旋多巴的病人慎用维生素B6,会使外周脱羧作用增强,增加外周副作用,减少中枢神经的作用。

(5)维生素B12针肌注禁用于痛风病人,可以诱发痛风急性发作;

(6)痛风急性期慎用别嘌呤醇,容易诱发痛风,因为使用后诱导嘌呤从痛风结节中游离出来,导致尿酸一过性增高,反而诱发发作加重。急性期过后,坚持服用。急性期可以使用激素、秋水仙碱或消炎止痛药物。

19、ATP静脉推注或麦入可能诱发心律失常或者心跳骤停。

(1)神经营养类药物(ATP)类慎用于心动过缓、癫痫患者以及脑梗死病人;速尿慎用于低钾患者;钙剂慎用于低钾患者;激素慎用于高血压及糖尿病患者;胺碘酮慎和西地兰合用;肾功能差者禁用依达拉奉;

(2)肝功能不全的癫痫患者慎用丙戊酸钠或丙戊酸镁,可以用咪唑达仑、异丙酚;肝性脑病忌用安定??抑制呼吸;呼吸衰竭、肝衰、急性酒精中毒等所导致的烦躁,慎用安定;静推安定速度宜慢;小剂量的溶媒如盐水或糖溶解安定会使溶液混浊;

(3)呼吸衰竭的癫痫患者慎用安定,可以用丙戊酸钠或丙戊酸镁或苯妥因钠。静脉推注氨茶碱切记慢,最好推注时间大于15-20分钟,否则可能导致心跳骤停。

20、癫痫患者慎用喹诺酮类抗生素,因此类药物有可能引起痫性发作;癫痫患者慎用泰能,可以用倍能替代;忌用皮质类固醇激素(对成人而言);脑活素禁用于癫痫病人。在一些患有神经肌肉阻滞相关疾病的患者中,慎用喹诺酮类抗生素,有诱发癫痫的可能;慎用氨基糖甙类药物。石杉碱甲禁用于哮喘,促脑代谢类慎用于癫痫。临床上经常碰到病脑的,既有癫痫发作又有顽固的精神症状,注意控制精神症状禁用氯丙嗪(可以诱发癫痫)。

21、抗癫痫药:苯巴比妥为肝药酶诱导剂,因此可使氢化可的松、地塞米松、睾丸酮、雌激素、孕激素、口服避孕药、氯丙嗪、氯霉素、多西环素、地高辛、洋地黄毒甙及苯妥英钠等药合用时代谢加速疗效降低.丙戊酸钠可抑制苯妥英钠、苯巴比妥、扑米酮、氯硝西泮的代谢,易使其中毒,故在合用时应注意调整剂量。卡马西平与苯巴比妥、苯妥英钠合用时,可加速卡马西平的代谢,使其浓度降低。抗抑郁药、大环内酯类抗生素、异烟肼、西咪替丁等药均可使卡马西平的血药浓度升高,使之易出现毒性反应。叶酸能加重癫痫发作。

22、抗癫痫药物导致的癫痫加重:卡马西平、苯妥英钠、苯巴比妥钠等可能加重失神发作;卡马西平、苯妥英钠可能加重肌阵挛加重;拉莫三嗪可能导致肌阵挛加重;妥泰可能导致儿童认知功能减退,低热、无汗。苯妥英钠会导致齿龈增生,多毛,丑陋面容,除非经济条件有限,一般儿童和女性患者不太用;苯妥英钠和苯巴比妥会加速口服避孕药的代谢,导致避孕失败;丙戊酸钠可能会导致体重增加,爱美的女士或者较胖的人也不建议用,如果有合适,可以用妥泰,但体重可能会下降;孕妇禁用丙戊酸钠;抑郁或帕金森病患者忌用西比灵;另外,老年患者或有认知功能障碍的患者尽量不要用安坦。卡马西平有抑制骨髓,降低白细胞作用。低血钙(假旁减等)的癫痫患者不用卡马西平、苯巴比妥和苯妥英钠等肝酶诱导剂,因后者能降低血钙。

23、抗震颤麻痹药金刚烷胺:有癫痫史,精神错乱,幻觉,充血性心力衰竭,肾功能不全,外周血管性水肿或直立性低血压的患者慎用;新生儿和1岁以下婴儿或哺乳期妇女禁用。(白加黑中含有该成分,不知道有没有太大的影响??)息宁:严重的心血管病或肺病,支气管哮喘,肝肾疾病,内分泌系统疾病,有胃溃疡或惊厥史者及孕妇慎用;狭角型青光眼,疑有皮肤癌或黑素瘤病史的病人禁用。

24、抗生素的使用:

(1)β-内酰胺类药物不可与酸性或碱性药物配伍 输液时只能用生理盐水溶解药物,不能用葡萄糖注射液溶解。

(2)头孢菌素类(特别是第一代头孢菌素)不可与高效利尿药(如速尿)联合应用,防止发生严重的肾损害。

(3)去甲万古霉素与许多药物可产生沉淀反应,因此含本品的输液中不得添加其他药物。

(4)磺胺注射液药物如磺胺嘧啶注射液,不易与酸性药物,如Vb、青霉素、四环素、盐酸麻黄碱等合用,否则析出磺胺沉淀,遇5%的碳酸氢钠注射液,析出磺胺沉淀。固体剂型遇普鲁卡因疗效减弱甚至失效,遇氧化钙、氯化铵会增加对泌尿系统毒性。 (5)应用头孢类抗生素需暂时忌酒??双硫仑样反应。

(6)低钾性周期麻痹慎用氨基糖甙类和克林霉素;

(7)有神经肌肉阻滞的病人,如格林巴利综合征,抗感染药物不能用克林霉素,因克林霉素可以阻滞神经肌肉接头处。

(8)阿奇霉素和茶碱同用应谨慎,和苄丙酮同时使用会增加抗凝药的药效,可以升高地高辛水平和麦角胺或二氢麦角胺合用可导致急性麦角毒性症状:

(9)严重的末梢血管痉挛和感觉迟钝,可以提高血清中卡马西平、特非那定、环孢素、苯妥英钠的水平。

(10)左氧氟沙星可导致血糖和肝功能异常。

(11)喹诺酮与丹参续滴时应注意,会出现絮壮沉淀;氨苄青霉素也可能会引起患者出现难治性药疹。

25、12类不能合用的药品:优降糖和阿司匹林;消炎痛和阿司匹林;胃舒平和多酶片;立特灵和麻黄;土霉素和保和丸;速效伤风胶囊和解热止痛药;解热止痛药和感冒清热冲剂;盐酸黄连素和牛黄解毒丸;磺胺类药和酸性中药神曲;广谱抗生素和浓缩的维生素A;红霉素和穿心莲;抗菌药和补钙、铝、铁的药品。

26、胃复安的绝对禁忌症有嗜咯细胞瘤、乳腺癌化疗后;胃复安与解痉药不能合用,如果合用则会抵消胃复安的作用。甲氰米胍老年人应用后有可能会出现幻觉。胃溃疡病人慎用培它司啶。急性脑血管病时慎用西咪替丁预防急性胃粘膜病变,重者可改用奥美拉唑静推,轻者予以口服。因它可通过血脑屏障,具有一定的神经毒性,较常见的有头晕、头痛、疲乏、嗜睡等症状。少数病人可出现不安、感觉迟钝、语言含糊不清、出汗、局部抽搐或癫痫样发作,以及幻觉、妄想等症状;可有心动过缓、面部潮红等。静脉注射时偶有血压骤降、房性早搏、心跳呼吸骤停。

27、降血脂的他丁类和贝特类不可合用;他汀类药物可引起横纹肌溶解症,当服药他汀类药物的患者出现肌痛、肌无力,肌酸激酶明显升高时,应及时停药;长春西丁不用于心动过缓病人。

28、利多卡因大量应用后会出现短暂失语。鲁米钠禁用于肝肾功能严重障碍、支气管哮喘患者。10%水合氯醛禁用于动脉硬化、肾炎、肝病。;罂粟碱禁用于房室传导阻滞病人;尼美舒利(普威)可引起面部浮肿。对有泥沙样小胆结石的老年患者,使用消炎利胆片时应注意,有可能会出现胆管嵌顿导致急性胆源性胰腺炎。

29、应用华发令进行抗凝治疗,如肺血栓栓塞,和房颤的病人长期抗凝治疗可以选用华法令口服,并需要检测INR值。在应用华法令的时候,需要注意,源于华法令的早期应用会导致机体暂时性,一过性的高凝状态(蛋白 C, 蛋白S消耗)所以在开始应用华法令的前3到五天需要合并应用肝素皮下注射抗凝治疗。一方面因为华法令起效较慢,另一方面因为其所导致的一过性,暂时性的高凝状态。应用华法令导致出血时,虽然大家都会想到给于维生素K 拮抗华法令的作用,然而这会给后续的抗凝治疗带来麻烦。所以此时多可停药。继续观察,如果出血量大,呈活动性,可考虑选用新鲜血浆,补充凝血因子。低分子右旋糖苷可能会引起患者出现难治性药疹应慎用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-02-19 1de522f9m41(暂无匿称)

    收藏

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-02-19 1de522f9m41(暂无匿称)

    收藏了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053665, encodeId=46e4205366547, content=<a href='/topic/show?id=982169e0540' target=_blank style='color:#2F92EE;'>#用药禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69705, encryptionId=982169e0540, topicName=用药禁忌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Fri Sep 16 23:00:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721378, encodeId=639b1e2137823, content=<a href='/topic/show?id=4ebee42046d' target=_blank style='color:#2F92EE;'>#神经内科#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74204, encryptionId=4ebee42046d, topicName=神经内科)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=972532995173, createdName=sodoo, createdTime=Wed Jan 06 04:00:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64746, encodeId=5eae64e463c, content=收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:10:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64745, encodeId=7f3064e45cd, content=收藏了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9c3d1688961, createdName=1de522f9m41(暂无匿称), createdTime=Fri Feb 19 09:02:00 CST 2016, time=2016-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545077, encodeId=307d15450e761, content=<a href='/topic/show?id=b7abe4635e0' target=_blank style='color:#2F92EE;'>#禁忌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74635, encryptionId=b7abe4635e0, topicName=禁忌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9513684874, createdName=thinkibmz_44722598, createdTime=Thu Dec 31 05:00:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50164, encodeId=37165016475, content=收着, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Tue Dec 29 14:20:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 xiaotaiyang1

    收着

    0